Enzalutamide

SHENZHEN, China, June 23, 2026 /PRNewswire/ -- From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm (688136.SH) showcased multiple self-developed innovative drug pipelines and over 30 products for international markets at the exhibition. The company was also invited to attend the CPHI Award ceremony and received the R&D Innovation Award for its achievements in innovation and international development. Multi-field Product Coverage and Recognition with Innovation Awards Its exhibited products spanned the fields of oncology, autoimmunity, and metabolic diseases. Blockbuster drugs such as albumin-bound paclitaxel, bevacizumab, infliximab, enzalutamide, aflibercept, liraglutide, and semaglutide received extensive consultations. Regarding the R&D pipeline, Kexing Biopharm highlighted several global innovative drug pipelines, encompassing GB18 for cancer cachexia, GB19/GB26 for systemic lupus erythematosus, GB10 for ophthalmology, and GB20/GB24 for autoimmune disorders. In addition, the clinical progress for two Phase III programs—long-acting GC and GB05 (interferon inhalation solution)—garnered significant attention. Years of steady development in technology platforms and innovative breakthroughs culminated in the company being honored with the R&D Innovation Award. Collaboratively presented by the organizers and industry authorities, this award employs a multi-dimensional assessment covering R&D innovation, clinical translation breakthroughs, technological application, and market impact. It serves as both a recognition of industrial innovation achievements and an insight into future trends and directions in pharmaceutical R&D. Gathering at Forums to Accelerate International Business Matchmaking At this event, the BD team of Kexing Biopharm was highly involved in premier forums and roundtables dedicated to global pharmaceutical expansion. By exploring cutting-edge issues like the international commercialization of Chinese biopharmaceuticals, the team highlighted the company's platform successes. These exchanges provided vital industry perspectives and references for optimizing the company's internationalization pathways and seizing global market opportunities. On the evening of June 15, Kexing Biopharm hosted a gathering for customers and partners from multiple countries. Participants engaged in relaxed yet in-depth discussions on market dynamics, cooperation prospects, and future strategic planning, laying a solid foundation of mutual trust and win-win collaboration for future endeavors. CPHI provides a strategic platform for Kexing Biopharm to showcase its strengths and forge connections with the global pharmaceutical market. Moving forward, the company will continue to deepen its global presence and collaborate with global partners to bring more high-quality products to a broader international market. SOURCE Kexing Biopharm 21% more press release views with Request a Demo

Steve van Os, MD Steve van Os, MD, appointed new Chief Medical Officer of Arlette Pharma Solutions Seasoned biotech executive brings more than two decades of global clinical development, medical affairs and regulatory leadership across oncology, women’s health and endocrinology Appointment supports Arletta’s next chapter as the company prepares the proposed U.S. Phase II Monarch study for Lybrido™ Dr. van Os brings senior development leadership experience spanning Astellas, Organon, Schering-Plough, Antev, Millicent Pharma and biotech advisory work His background includes global registration leadership, IND filings, regulatory negotiations and oversight of multinational development programs Amsterdam, the Netherlands, 19 June 2026 -- Arletta Pharma Solutions , a biopharmaceutical company specializing in innovative therapies for women diagnosed with Female Sexual Disorders (FSD), today announced the appointment of Steve van Os, MD ( picture ), as Chief Medical Officer, effective June 1 st . Dr. van Os joins Arletta at a pivotal moment as the company prepares its proposed U.S. Phase II Monarch study of Lybrido™, its lead investigational therapy for women with Female Sexual Interest/Arousal Disorder (FSIAD) and Hypoactive Sexual Desire Disorder (HSDD). In his role as Chief Medical Officer, Dr. van Os will lead Arletta’s medical strategy, clinical development oversight, study execution support, safety oversight and regulatory interactions as the company advances Monarch and broader development plans for Lybrido™ in the United States and Europe. Dr. van Os is a seasoned biopharmaceutical executive with more than two decades of global experience in clinical development, medical affairs and regulatory strategy across oncology, urology, women’s health, endocrinology and hepatology. At present he serves as Head of Medical Affairs at Millicent Pharma and as Chief Medical Officer at UPyTher, advising through Van Os Medical Consultancy on clinical development strategy and regulatory interactions, particularly in oncology with a specialization in prostate and breast cancer. Dr. van Os earned his MD in Medicine from Utrecht University, The Netherlands. Previously, Dr. van Os served as Chief Medical Officer of Antev Limited, where he led medical strategy, patient safety oversight, development planning, study conduct, reporting, regulatory strategy and agency interactions for teverelix in prostate cancer and urology. During his tenure, he finalized the Phase II study report in prostate cancer, supported two new IND filings and co-authored three peer-reviewed publications. Earlier in his career, Dr. van Os spent more than ten years at Astellas Pharma, including as Senior Director, Global Development Oncology, where he was globally accountable for the clinical development and registration of enzalutamide (Xtandi) for men with prostate cancer in more than 100 countries. He led a global development team that achieved registrations in 97 countries and played key roles in agency interactions with the FDA, EMA, PMDA and CFDA. He also previously held senior positions at Organon, Schering-Plough and Yamanouchi, with responsibilities across gynecology, menopause, osteoporosis, breast cancer and broader clinical development operations. Manuel Voll, MsC, Chairman of Arletta’s Supervisory Board, said: “Steve brings the rare combination of strategic development leadership, operational discipline and regulatory depth that we need at exactly this point in Arletta’s evolution. As we prepare to open a new chapter with the proposed U.S. Phase II Monarch study for Lybrido™, his track record across global programs, biotech innovation and cross-functional execution will be immensely valuable.” Steve van Os, MD, commented: “I am excited to join Arletta at this important stage in its development. Women with FSIAD and HSDD continue to face major unmet medical needs, and I believe Arletta has the scientific foundation and strategic clarity to make a meaningful difference. I look forward to working with the team to advance Lybrido™ through its next stage of development.” === E N D S === About Monarch Monarch is the proposed name for Arletta’s U.S. Phase II clinical study for Lybrido™ and is intended to support the next stage of the company’s development strategy. The study name aligns with Arletta’s butterfly-inspired brand identity and symbolizes transition, progression and focused forward momentum. About Lybrido™ Lybrido™ is an investigational on-demand, dual-action therapy designed to address both the psychological and physiological components of Female Sexual Interest/Arousal Disorder (FSIAD) and Hypoactive Sexual Desire Disorder (HSDD). The treatment consists of a novel dual-route, dual-release fixed-dose combination with testosterone for sublingual administration and sildenafil in a delayed-immediate-release core designed to synchronize sexual motivation and genital arousal responses. About Arletta Pharma Solutions Arletta Pharma Solutions is a pharmaceutical company, previously known as Freya Pharma Solutions, focused on developing effective pharmaceutical therapies for FSIAD/HSDD, building upon more than fifteen years of rigorous scientific research. The company's core asset under development is Lybrido™, designed to address FSIAD/HSDD through an innovative on-demand dual-action mechanism that targets both psychological and physiological components of female sexual dysfunction. Based in Amsterdam, The Netherlands, Arletta Pharma Solutions aims to offer patients a convenient, personalized on-demand solution for this recognized unmet medical need affecting millions of women worldwide. The company's name, derived from a rare butterfly species, symbolizes transformation, beauty, and freedom, concepts that resonate deeply with women's healthcare and the company's mission to empower women to take control of their sexual health. For further information please contact: Arletta Pharma Solutions, Amsterdam, the Netherlands Marcel Wijma, Chief Business Officer marcel@arlettapharmasolutions.com For media: LifeSpring Life Sciences Communication, Amsterdam, the Netherlands Leon Melens T: +31 6 538 16 427 E: lmelens@lifespring.nl This press release contains forward-looking statements regarding Arletta Pharma Solutions’ clinical development plans, regulatory strategy and future prospects. Actual results may differ materially from those projected. Lybrido™ is an investigational product that has not been approved by any regulatory authority. Attachment Steve van Os, MD